Stock Market Reviews

MGTX (MeiraGTx Holdings plc) News

Get the latest news, insights, and market updates on MGTX (MeiraGTx Holdings plc). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
  ZipBio, a biotechnology company pioneering AI-driven protein therapeutics, announced an exclusive license agreement with MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company. Under the agreement, MeiraGTx will receive exclusive rights to ZipBio's first-in-class therapies for Geographic Atrophy, targeting the complement pathway.
  Feb 3, 2026 - $MGTX
• MeiraGTx Holdings plc (NASDAQ:MGTX) has caught the attention of institutional investors who hold a sizeable 31% stake
  Key Insights Institutions' substantial holdings in MeiraGTx Holdings implies that they have significant influence over...
  Dec 16, 2025 - $MGTX
• Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference
  Graviton Bioscience Corporation, a clinical-stage biotechnology company developing selective ROCK2 inhibitors for metabolic, inflammatory, fibrotic, and central nervous system disorders, among other therapeutic indications, today announced that Samuel Waksal, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore HealthCONx Conference. Details of the fireside chat are as follows:
  Nov 20, 2025 - $MGTX
• MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
  Entered into broad strategic collaboration with Eli Lilly and Company (“Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company’s AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 (LCA4) Released material under the Company’s Specials license for a second rare pediatric ophthalmology condition caused by mutations in BBS10, with the prescribing physician treating the first patient during the quarte
  Nov 13, 2025 - $MGTX
• Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates
  Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of +11.32% and +57.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 10, 2025 - $MGTX
• MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
  LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in the area of ophthalmology with Eli Lilly and Company (“Lilly”). MeiraGTx will grant Lilly worldwide exclusive rights to its AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 (LCA4) owing to genetic deficiency of Aryl-hydrocarbo
  Nov 10, 2025 - $MGTX
• Alector (ALEC) Reports Q3 Loss, Beats Revenue Estimates
  Alector (ALEC) delivered earnings and revenue surprises of +19.05% and +24.19%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 6, 2025 - $MGTX
• MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
  MeiraGTx (MGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Nov 5, 2025 - $MGTX
• Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates
  Gossamer Bio (GOSS) delivered earnings and revenue surprises of -10.53% and +118.76%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 5, 2025 - $MGTX
• MeiraGTx (MGTX) Moves 12.4% Higher: Will This Strength Last?
  MeiraGTx (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
  Oct 22, 2025 - $MGTX